A new front against MYC-driven disease P2K Dynamics is developing PIM2-directed medicines designed to disrupt oncogenic signaling in multiple myeloma and other hematological cancers.

01 Approach

Where models propose, biology decides

Our discovery process pairs proprietary AI-enabled predictive insight with multi-disciplinary drug discovery and development, allowing evidence to guide every decision.

01Need
02Route
03Lead
  1. Clinical need

    Multiple myeloma remains incurable, and most patients eventually relapse. In malignant plasma cells, PIM2 is highly expressed while MYC drives proliferation and survival.

  2. Druggable control point

    Direct MYC inhibition is constrained by its lack of a stable binding pocket. PIM2 provides a druggable control point for cMYC abundance and promoter activity.

  3. Dual-profile activity

    Building on this connection, we aim to develop first-in-class therapies for MYC-driven disease that can act with or without inhibiting PIM2 kinase activity.

Building c-MYC structure

02 Program

Precision begins with the right target

Our PIM2 modulators downregulate PIM2 and MYC expression and demonstrate potent activity across multiple myeloma cell lines, including MM.1S, with activity extending to other hematologic and solid tumor models.

03 Innovation

Many models One discovery engine

Krebs is our in-house agentic AI platform, coordinating proprietary models trained on kinase-focused protein data to prioritize promising directions and move drug discovery forward with greater speed and focus.

The Krebs agentic medicinal chemistry interface